Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Cancer in patients with rheumatic diseases exposed to TNF antagonists.

Carmona L, Abasolo L, Descalzo MA, Pérez-Zafrilla B, Sellas A, de Abajo F, Gomez-Reino JJ; BIOBADASER Study Group; EMECAR Study Group.

Semin Arthritis Rheum. 2011 Aug;41(1):71-80. doi: 10.1016/j.semarthrit.2010.08.005. Epub 2010 Nov 18.

PMID:
21093020
2.

Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists.

García-Doval I, Pérez-Zafrilla B, Descalzo MA, Roselló R, Hernández MV, Gómez-Reino JJ, Carmona L; BIOBADASER 2.0 Study Group.

Ann Rheum Dis. 2010 Oct;69(10):1751-5. doi: 10.1136/ard.2009.125658. Epub 2010 Jun 15.

PMID:
20551153
3.

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.

Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, Carreño L, Figueroa M; BIOBADASER Group.

Arthritis Rheum. 2005 Jun;52(6):1766-72.

4.

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.

Gómez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group.

Arthritis Rheum. 2007 Jun 15;57(5):756-61.

5.

Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy.

Peña-Sagredo JL, Fariñas MC, Perez-Zafrilla B, Cruz-Valenciano A, Crespo M, Joven-Ibañez B, Riera E, Manero-Ruiz FJ, Chalmeta I, Hernández MV, Rodríguez-Gómez M, Maíz O, López R, Cobo T, Pita J, Carmona L, Gonzalez-Gay MA; BIOBADASER and EMECAR Groups.

Clin Exp Rheumatol. 2009 Nov-Dec;27(6):920-5.

PMID:
20149306
6.

Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.

Cruz Fernández-Espartero M, Pérez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gómez-Reino JJ, Carmona L; BIOBADASER Study Group.

Semin Arthritis Rheum. 2011 Dec;41(3):524-33. doi: 10.1016/j.semarthrit.2011.05.003. Review.

PMID:
22152489
7.
8.

Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.

Hernández MV, Sanmartí R, Cañete JD, Descalzo MA, Alsina M, Carmona L, Gomez-Reino JJ; BIOBADASER 2.0 Study Group.

Arthritis Care Res (Hoboken). 2013 Dec;65(12):2024-31. doi: 10.1002/acr.22096.

9.

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.

Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, Gómez-Reino JJ; BIOBADASER and EMECAR Groups.

Ann Rheum Dis. 2007 Jul;66(7):880-5. Epub 2007 Feb 26.

10.

Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0.

Carmona L, Descalzo MA, Ruiz-Montesinos D, Manero-Ruiz FJ, Perez-Pampin E, Gomez-Reino JJ; BIOBADASER 2.0 Study Group.

Rheumatology (Oxford). 2011 Jan;50(1):85-92. doi: 10.1093/rheumatology/keq207. Epub 2010 Jul 3.

PMID:
20601654
11.

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundström C, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, Feltelius N.

Ann Rheum Dis. 2005 Oct;64(10):1414-20. Epub 2005 Apr 20.

12.

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.

Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N.

Arthritis Rheum. 2005 Jul;52(7):1986-92.

13.

Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.

Ljung L, Simard JF, Jacobsson L, Rantapää-Dahlqvist S, Askling J; Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group.

Arthritis Rheum. 2012 Jan;64(1):42-52. doi: 10.1002/art.30654.

14.
15.
16.

Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0.

Gómez-Reino JJ, Rodríguez-Lozano C, Campos-Fernández C, Montoro M, Descalzo MÁ, Carmona L; BIOBADASER 2.0 Study Group.

Ann Rheum Dis. 2012 Mar;71(3):382-5. doi: 10.1136/annrheumdis-2011-200302. Epub 2011 Oct 13.

PMID:
21998116
17.

Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry.

Busquets N, Tomero E, Descalzo MÁ, Ponce A, Ortiz-Santamaría V, Surís X, Carmona L, Gómez-Reino JJ; BIOBADASER 2.0 Study Group.

Rheumatology (Oxford). 2011 Nov;50(11):1999-2004. doi: 10.1093/rheumatology/ker281. Epub 2011 Aug 19.

PMID:
21856725
18.

Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry.

Pallavicini FB, Caporali R, Sarzi-Puttini P, Atzeni F, Bazzani C, Gorla R, Marchesoni A, Favalli EG, Montecucco C.

Autoimmun Rev. 2010 Jan;9(3):175-80. doi: 10.1016/j.autrev.2009.07.006. Epub 2009 Jul 30.

PMID:
19647103
19.

Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.

Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, Kim TH, Jun JB, Yoo DH, Lee JT, Bae SC.

J Rheumatol. 2007 Apr;34(4):706-11. Epub 2007 Feb 15.

PMID:
17309133
20.

Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis.

Al-Aly Z, Pan H, Zeringue A, Xian H, McDonald JR, El-Achkar TM, Eisen S.

Transl Res. 2011 Jan;157(1):10-8. doi: 10.1016/j.trsl.2010.09.005. Epub 2010 Oct 21.

PMID:
21146146

Supplemental Content

Support Center